{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:09Z","timestamp":1787387049260,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03624-1","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:30:34Z","timestamp":1782297034000},"page":"3913-3928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Criteria Clinicians Use to Classify Patients as High Risk in Biochemically Recurrent Nonmetastatic Castration\u2011Sensitive Prostate Cancer"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-8737","authenticated-orcid":false,"given":"Amanda","family":"Ribbands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblys","family":"Touya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-1443","authenticated-orcid":false,"given":"Jake","family":"\u00a0Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8296-4784","authenticated-orcid":false,"given":"Maria","family":"Walley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Bland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina \u00a0I.","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"1","key":"3624_CR1","first-page":"14","volume":"11","author":"CJ Paller","year":"2013","unstructured":"Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11(1):14\u201323.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"3624_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","volume":"172","author":"KA Roehl","year":"2004","unstructured":"Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910\u20134. https:\/\/doi.org\/10.1097\/01.ju.0000134888.22332.bb.","journal-title":"J Urol"},{"issue":"2 Pt 1","key":"3624_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/s0022-5347(01)69079-7","volume":"167","author":"GW Hull","year":"2002","unstructured":"Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167(2 Pt 1):528\u201334. https:\/\/doi.org\/10.1016\/s0022-5347(01)69079-7.","journal-title":"J Urol"},{"issue":"1","key":"3624_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","volume":"164","author":"CL Amling","year":"2000","unstructured":"Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000;164(1):101\u20135.","journal-title":"J Urol"},{"issue":"3","key":"3624_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","volume":"68","author":"PA Kupelian","year":"2006","unstructured":"Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68(3):593\u20138. https:\/\/doi.org\/10.1016\/j.urology.2006.03.075.","journal-title":"Urology"},{"issue":"4","key":"3624_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433\u20139. https:\/\/doi.org\/10.1001\/jama.294.4.433.","journal-title":"JAMA"},{"issue":"17","key":"3624_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1591.","journal-title":"JAMA"},{"issue":"38","key":"3624_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/EDBK_200319","volume":"38","author":"DE Spratt","year":"2018","unstructured":"Spratt DE, McHugh DJ, Morris MJ, Morgans AK. Management of biochemically recurrent prostate cancer: ensuring the right treatment of the right patient at the right time. Am Soc Clin Oncol Educ Book. 2018;38(38):355\u201362. https:\/\/doi.org\/10.1200\/EDBK_200319.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"3624_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","volume":"109","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109(1):32\u20139. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10422.x.","journal-title":"BJU Int"},{"issue":"5 Suppl","key":"3624_CR10","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.juro.2008.03.138","volume":"179","author":"JW Moul","year":"2008","unstructured":"Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2008;179(5 Suppl):S53\u20139. https:\/\/doi.org\/10.1016\/j.juro.2008.03.138.","journal-title":"J Urol"},{"issue":"6","key":"3624_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review. Eur Urol. 2019;75(6):967\u201387. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.011.","journal-title":"Eur Urol"},{"issue":"6","key":"3624_CR12","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","journal-title":"J Urol"},{"issue":"11","key":"3624_CR13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.20.03256","volume":"39","author":"KS Virgo","year":"2021","unstructured":"Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2021;39(11):1274\u2013305. https:\/\/doi.org\/10.1200\/JCO.20.03256.","journal-title":"J Clin Oncol"},{"key":"3624_CR14","unstructured":"Cornford P, Tilki D, van den Bergh RCN, Briers E, Patient Advocate (European Prostate Cancer Coalition\/Europa UOMO), Eberli D, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. EAU Guidelines Edn presented at the EAU Annual Congress Paris April 2024 ISBN 978\u201394\u201392671\u201323\u20133. Arnhem, the Netherlands: EAU Guidelines Office; 2024"},{"issue":"16","key":"3624_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"issue":"6","key":"3624_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa2510310","volume":"394","author":"ND Shore","year":"2026","unstructured":"Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2026;394(6):563\u201375.","journal-title":"N Engl J Med"},{"key":"3624_CR17","unstructured":"Astellas Pharma US Inc.: Full prescribing information: XTANDI\u00ae (enzalutamide) for oral use. https:\/\/www.astellas.us\/docs\/us\/12A005-ENZ-WPI.pdf (2025). Accessed February 5 2026."},{"key":"3624_CR18","unstructured":"European Medicines Agency: Xtandi. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xtandi (2025). Accessed Feb 5 2026."},{"key":"3624_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102630","volume":"122","author":"JA Efstathiou","year":"2024","unstructured":"Efstathiou JA, Morgans AK, Bland CS, Shore ND. Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer. Cancer Treat Rev. 2024;122:102630. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102630.","journal-title":"Cancer Treat Rev"},{"issue":"34","key":"3624_CR20","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO-25-01693","volume":"43","author":"DJ Einstein","year":"2025","unstructured":"Einstein DJ, Abel ML, Aragon-Ching JB, Arlen PM, Autio KA, Bilusic M, et al. National Cancer Institute\u2019s Working Group on Biochemically Recurrent Prostate Cancer: clinical trial design considerations. J Clin Oncol. 2025;43(34):3672\u201383. https:\/\/doi.org\/10.1200\/JCO-25-01693.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3624_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/JU.0000000000004905","volume":"215","author":"T Hunt","year":"2026","unstructured":"Hunt T, Malshy K, Bandari J. Editorial comment RE: \u201cTreatment of high-risk biochemically recurrent Prostate Cancer with Enzalutamide in combination with leuprolide: secondary endpoints from the EMBARK trial.\u201d J Urol. 2026;215(5):522\u20133. https:\/\/doi.org\/10.1097\/JU.0000000000004905.","journal-title":"J Urol"},{"issue":"5","key":"3624_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/JU.0000000000004961","volume":"215","author":"ND Shore","year":"2026","unstructured":"Shore ND, Freedland SJ. Reply by authors. J Urol. 2026;215(5):523. https:\/\/doi.org\/10.1097\/JU.0000000000004961.","journal-title":"J Urol"},{"issue":"1","key":"3624_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41391-025-00959-8","volume":"29","author":"U De Giorgi","year":"2026","unstructured":"De Giorgi U, Freedland SJ, Rannikko A, Ramirez-Backhaus M, Villers A, Tarazi J, et al. Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK. Prostate Cancer Prostatic Dis. 2026;29(1):198\u2013201. https:\/\/doi.org\/10.1038\/s41391-025-00959-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"3624_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41391-023-00711-0","volume":"27","author":"JW Moul","year":"2024","unstructured":"Moul JW, Shore ND, Pienta KJ, Czernin J, King MT, Freedland SJ. Application of next-generation imaging in biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2024;27(2):202\u201311. https:\/\/doi.org\/10.1038\/s41391-023-00711-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"3624_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, et al. PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw Open. 2025;8(1):e2452971. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.52971.","journal-title":"JAMA Netw Open"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03624-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03624-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03624-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:32Z","timestamp":1787385872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03624-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3624"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03624-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephen J. Freedland: consulting or advisory role with Astellas Pharma Inc., AstraZeneca, Bayer, Eli Lilly, Exact Sciences, Johnson & Johnson Innovative Medicine (formerly Janssen), Merck, Novartis, Pfizer Inc., Sanofi, and Sumitomo Pharma America, Inc. (formerly Myovant Sciences). Amanda Ribbands, Jake Butcher, Maria Walley: employees of Adelphi Real World. Ma\u00eblys Touya: employee and shareholder of Astellas Pharma Inc. David Russell, Jasmina I. Ivanova: employees and shareholders of Pfizer Inc. Christopher S. Bland: former employee of Pfizer Inc. Current affiliation: Ipsen Pharma, Cambridge, MA, USA.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Pearl International Review Board provided exemption for the ARW independent retrospective nmCSPC survey (reference number 2023-0099). Consent was provided by the physicians via a check box, which they ticked, acknowledging their participation in the survey. All participants were informed of how their data would be used and that they had the right to withdraw at any time. Participants were also informed that the results from the survey may be used for publication in scientific journals. No additional consent or approval was required due to the secondary nature of the data analyzed. All data were fully de-identified and aggregated before receipt and analysis by ARW. Data collection was conducted in full accordance with the European Pharmaceutical Market Research Association guidelines and the US Health Insurance Portability and Accountability Act 1996, as well as the Health Information Technology for Economic and Clinical Health Act legislation.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}